Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.

Constantine Tam, Bryone Kuss, Stephen Opat, Joy Boulos, Paula Marlton

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered ‘unfit’ for fludarabine–cyclophosphamide–rituximab therapy. In these patients, the combination of obinutuzumab–chlorambucil may be an appropriate therapeutic choice. Obinutuzumab–chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab–chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab–chlorambucil.

    Original languageEnglish
    Pages (from-to)5-10
    Number of pages6
    JournalInternal Medicine Journal
    Volume47
    DOIs
    Publication statusPublished - 2017

    Fingerprint Dive into the research topics of 'Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.'. Together they form a unique fingerprint.

  • Cite this